Bulking agents contribute to the volume of a product without altering its fundamental characteristics. In food, pharmaceuticals, and cosmetics, they ensure the right quantity without compromising quality.
Anti-crystallizing agents prevent the formation of unwanted crystals, maintaining the purity of substances like sugar, honey, or pharmaceutical ingredients.
Did you know ?
In the world of confectionery, anti-crystallizing agents play a pivotal role in achieving the smooth texture of chocolates, preventing the formation of sugar crystals.
PVP K-30
Other products are available based on customer requirements
Expert answers about PVP K-30 as a bulking and anti-crystallizing agent in pharmaceutical formulations.
PVP K-30 (Polyvinylpyrrolidone) functions as a bulking agent by providing the necessary mass and volume to small-dose drug formulations, enabling uniform blending and accurate dosing. Its high compressibility and binding properties make it ideal for tablet formulations where the active ingredient constitutes only a small fraction of the tablet weight. PVP also acts as a dry binder, improving tablet hardness without compromising disintegration.
PVP K-30 inhibits drug crystallization through intermolecular hydrogen bonding between its carbonyl groups and the drug's functional groups. This interaction disrupts the drug's ability to form an ordered crystal lattice, maintaining it in a thermodynamically stable amorphous state. PVP also increases the glass transition temperature of the drug-polymer mixture, reducing molecular mobility and delaying the onset of crystallization during storage.
In solid dispersions, PVP K-30 acts as a hydrophilic carrier that disperses drug molecules at the molecular level within a polymer matrix. During dissolution, the water-soluble PVP dissolves rapidly, releasing drug molecules as fine particles or in supersaturated solution. This creates a high-energy amorphous state with dramatically increased surface area and apparent solubility compared to the crystalline drug form.
For effective crystallization inhibition, PVP K-30 is typically used at drug-to-polymer ratios ranging from 1:1 to 1:4 w/w. The optimal ratio depends on the drug's crystallization tendency — weakly crystallizing drugs may require only 1:1 ratios, while strongly crystallizing drugs may need higher polymer concentrations. A minimum of 10-20% w/w PVP relative to the drug is generally needed to achieve significant crystallization inhibition.
PVP K-30 enhances bioavailability by maintaining drugs in their amorphous state, which has higher apparent solubility than crystalline forms. It also improves drug wettability through its hydrophilic nature, enhances dissolution rates in gastrointestinal fluids, and can create supersaturated drug concentrations that improve absorption. The polymer's ability to inhibit precipitation ensures that the enhanced solubility is maintained throughout the gastrointestinal transit time.
PVP K-30